Welcome to our dedicated page for Silexion Therapeutics news (Ticker: SLXN), a resource for investors and traders seeking the latest updates and insights on Silexion Therapeutics stock.
Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, with a lead focus on locally advanced pancreatic cancer. The news flow around Silexion centers on its progress with SIL204, a next-generation siRNA therapy designed to silence mutated KRAS oncogenes that drive aggressive solid tumors.
Readers following SLXN news can expect updates on preclinical data, regulatory milestones, and clinical trial preparations. Recent press releases have highlighted new human cancer cell line results demonstrating high inhibition across multiple KRAS mutations and organ sites, including pancreatic, colorectal, lung, and gastric cancer models. The company has also reported biodistribution and efficacy data in metastatic pancreatic cancer models, as well as completion of two-species toxicology studies that it states confirmed no systemic organ toxicity.
Another key theme in Silexion’s news is its regulatory and clinical development pathway for SIL204. The company has announced formal written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on the design of its planned Phase 2/3 trial in locally advanced pancreatic cancer, submission of a clinical trial application in Israel, and plans for additional submissions in Europe and the United States. Operational updates include selection of a contract research organization, manufacturing collaborations, and preparations for trial initiation.
In addition, Silexion’s news releases cover financing transactions, capital-raising activities, and Nasdaq listing matters, such as regaining compliance with minimum bid price and shareholders’ equity requirements. Investors and observers can use this news page to review company communications on scientific results, regulatory interactions, business developments, and conference presentations related to Silexion’s KRAS-focused RNAi oncology programs.
Silexion Therapeutics and Moringa Acquisition Corp have completed their business combination, forming Silexion Therapeutics Corp. The combined company's shares and warrants are set to trade on Nasdaq under tickers "SLXN" and "SLXNW" starting August 16, 2024. This merger, approved by Moringa shareholders on August 6, 2024, aims to provide Silexion with enhanced financial and strategic flexibility to advance its siRNA therapies for cancer treatment.
Following redemptions, 87,722 MACA public shares were exchanged for ordinary shares of the combined company. The transaction marks a significant milestone for Silexion, positioning it to further its mission of revolutionizing cancer treatment and improving patient outcomes.